1 A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1

2 and SMN2 variant analysis

- 3 Running title: Long read sequencing-based analysis of SMN1/SMN2
- 4 Brad Hall^{1*}, Sawsan Alyafei^{2*}, Sathishkumar Ramaswamy², Shruti Sinha², Maha El
- Naofal², Fatma Rabea^{2,3}, Bryan J. Killinger¹, Gary J. Latham¹, Ahmad Abou
 Tayoun^{2,4}
- 7
- ⁸ ¹Asuragen, A Bio-Techne Brand, Texas, USA
- ⁹ ²Genomics Center of Excellence, Al Jalila Children's Specialty Hospital, Dubai
- 10 Health, Dubai, UAE
- ¹¹ ³Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health,
- 12 Dubai, UAE
- ¹³ ⁴Center for Genomic Discovery, Mohammed Bin Rashid University of Medicine and
- 14 Health Sciences, Dubai Health, Dubai, UAE
- 15 *Equally contributed to this work
- 16

18

20

- 17 Corresponding Author: Ahmad Abou Tayoun; <u>Ahmad.Tayoun@dubaihealth.ae</u>
- 19 Keywords: Enrichment, Nanopore Sequencing, SMN1/2, SMA, Carrier Screening
- 21 Previously presented at Oxford Nanopore Technologies London Calling 2023
- 22
- 23 Word Count: 3523

- 25 5 Figures and Tables
- 26
- 27 Abbreviations:
- 28 SMA, Spinal Muscular Atrophy

- 29 SNVs, Single nucleotide variants
- 30 Indels, Insertions and deletions
- 31 CNVs, Copy number variants
- 32 NGS, Next generation sequencing
- 33 US, United States
- 34 FDA, Food and Drug Administration
- 35 HRM, High-resolution melt
- 36 MLPA, Multiplex ligation-dependent probe amplification
- 37 ONT, Oxford Nanopore Technologies
- 38 PCR, Polymerase chain reaction
- 39 gDNA, Genomic DNA
- 40 NHGRI, National Human Genome Research Institute
- 41 NIGMS, National Institute of General Medical Sciences
- 42 ddPCR, droplet digital PCR
- 43 CE, Capillary electrophoresis
- 44 QC, Quality control
- 45

46 Human Genes:

- 47 SMN1 survival of motor neuron 1, telomeric HGNC:11117
- 48 SMN2 survival of motor neuron 2, centromeric HGNC:11118
- 49 *CFTR* CF transmembrane conductance regulator HGNC:1884

50 Abstract

51 Background

52 Spinal Muscular Atrophy (SMA) is one of the most common recessive disorders for 53 which several life-saving treatment options are currently available. It is essential to 54 establish universal SMA screening and diagnostic programs using scalable, cost-55 effective and accessible platforms to accurately identify all variation types, which is 56 complicated by homologous *SMN1* and *SMN2* genes.

57 Methods

We developed a dual-mode PCR-based target enrichment that generates 2.7 to 11.2 kb amplicons spanning *SMN1* and *SMN2* genes for any-length nanopore sequencing. We trained a variant calling model that utilizes paralog-specific sequences and read-depth data to accurately detect sequence and copy number variants specific to each gene.

63 **Results**

64 We present results from the development, optimization, and external evaluation of 65 this assay using over 750 samples, including cell lines, residual presumed normal 66 blood donors, and patients with known SMN1 and SMN2 genotypes. The assay 67 detects SNVs, indels, and CNVs with >98% accuracy across all sample sets, with a 68 highly dynamic throughput range, relatively fast turnaround time, and limited hands-69 on-time. Together with the modest capital investment and consumable costs per 70 sample, this assay can help increase access to SMA testing in low- and middle-71 income settings.

72 **Conclusion**

We describe a PCR/Nanopore sequencing assay and a customized analysis pipeline
 for the comprehensive and accurate detection of variation at the SMA locus and

- 75 demonstrate its scalability, cost-effectiveness, and potential for the universal
- ⁷⁶ implementation of SMA screening and diagnostic programs.

78 Introduction

Spinal Muscular Atrophy (SMA) is the second most common autosomal recessive disease and the most common genetic cause of infant death (1). In around 95% of cases, SMA is caused by a homozygous deletion of the *SMN1* gene, which encodes for the survival motor neuron 1 protein (2, 3, 4); loss of this protein leads to degeneration of the motor neurons in the spinal cord and progressive muscle weakness, paralysis and, if untreated, premature death (5). Additional intragenic and structural variants have also been identified (6).

86

87 Both SMN1 and its paralog, SMN2 encode the same protein, SMN, and copy 88 numbers of each within the genome can range from zero to four or more. SMA 89 disease is modified by copy number status of the SMN2 gene, which has >99.9% 90 sequence identity to SMN1 (7), though it does not produce a functional product 91 because of a single nucleotide change in exon 7 that causes exon skipping and 92 produces a truncated, nonfunctional protein (8). However, due to leaky expression of 93 the full-length protein from the SMN2 locus, its copy number status is inversely 94 correlated with SMA clinical phenotype and disease severity (9, 8, 10). Patients at 95 the severe end of the spectrum (SMA type I) often have one copy of SMN2, while 96 those with a milder phenotype (SMA type IV) have greater than or equal to 4 copies 97 of this gene (9, 11, 5).

98

Given its prevalence, life-threatening outcomes and, most recently, the availability of
three life-saving medications approved by the US FDA (Zolgensma, Spinraza, and
Evyrsdi), genetic diagnostic and screening programs have become essential for risk
assessment, early detection, and timely patient treatment (12, 13). Such programs,

however, require rapid, accurate, and comprehensive testing platforms to unambiguously detect and resolve single nucleotide (SNVs) and copy number variants (CNVs) in the *SMN1* and *SMN2* genes, as well as complex rearrangements leading to gene conversions (14) and silent carriers (15).

107

SMA testing strategies should also be highly scalable, cost-effective, and not require significant capital investment or complex infrastructure to support the deployment of universal screening programs in low-resource settings (16). These qualities are not only essential for equitable global access to screening but also important for characterizing disease epidemiology (incidence, prevalence and carrier frequencies) across populations. Such information can then inform the most appropriate screening and prevention strategies (17).

115

116 Since SMN2 has high homology to SMN1, current screening methods such as NGS 117 often require complex analysis methods that are difficult to interpret and may not 118 accurately resolve SMN1 copy number variants. Targeted copy number methods 119 such as high-resolution melt (HRM) and multiplex ligation-dependent probe 120 amplification (MLPA) are not designed to detect many pathogenic variants (18, 6). 121 Recently, long-read sequencing has emerged as an option to identify copy number 122 and pathogenic variants in a single workflow (19; 20). Recent advancements in 123 sequencing technologies may help overcome these challenges by incorporating 124 much longer unique reads that can differentiate SMN1 from SMN2 via paralog-125 specific variants. However, such assays are limited by accessibility, capital costs, 126 and costly and complex operational infrastructure.

128 To address these limitations, we developed a complete assay and workflow for 129 SMN1 and SMN2 genetic analysis using targeted PCR amplification, Oxford 130 Nanopore (ONT) any-length sequencing, and a customized analytical algorithm that 131 resolves multiple variant classes. We report results with more than 750 samples 132 demonstrating high accuracy across diverse and complex genotypes. We also 133 discuss operational and real-world advantages for carrier screening and diagnostic 134 applications, including simple library preparation, flexible sample throughput, low 135 capital investment, small instrument footprint, and modest consumable cost per 136 sample.

137

138 Methods

139 Assay Prototyping cohort

140 The prototype assay was developed using genomic DNA (gDNA) from cell lines 141 (N=97) obtained from the Centers for Disease Control and Prevention Repository 142 (N=4), National Human Genome Research Institute (NHGRI) Sample Repository for 143 Human Genetic Research (N=12), and National Institute of General Medical 144 Sciences (NIGMS) Human Genetic Cell Repository (N=73) at the Coriell Institute for 145 Medical Research (Camden, NJ; Supplemental Table 1). Additionally, cell lines (N=8; described in 21) were procured from ATCC and isolated using a precipitation-146 147 based method (Qiagen, Hilden, Germany).

148

149 Assay Optimization cohort

Human-derived, presumed normal, de-identified residual whole blood specimens (N=227) were obtained from We Are Blood (Austin, TX) under the required regulatory approvals for evaluating clinical specimens. Whole blood was purified

using either silica resin/column-based method (Qiagen, Hilden, Germany) or functionalized magnetic bead (Applied Biosystems, Waltham, MA). Genomic DNA quantity (ng/uL) and quality (A_{260}/A_{280}) were assessed using spectrophotometry. Samples were diluted in nuclease-free water to the target concentration for analysis using the assay.

158

159 Assay Evaluation cohort

De-identified samples with known SMA copy number status as determined by clinical testing using a droplet digital PCR assay (see below) at the CAP-accredited genomics center, at Al Jalila Children's Specialty Hospital (Dubai, United Arab Emirates), were used for assay evaluation and test performance characterization. This study was approved by the Dubai Health Authority Research Ethics Committee (DSREC-07/2023 06 and DSREC-SR-03/2023 08).

166

167 **Droplet digital PCR**

Genomic DNA extracted from peripheral blood (N = 70) were tested for *SMN1* and *SMN2* copy number status using a proprietary droplet digital PCR (ddPCR) assay (Bio-Rad, USA) following manufacturer's instructions. This assay was clinically validated by the Al Jalila Children's genomics laboratory (22).

172

173 PCR and capillary electrophoresis (PCR/CE)

Only samples determined to have a homozygous deletion of the *SMN1* gene by ddPCR (N = 32) were clinically tested for *SMN2* copy number status by ddPCR. For the remaining samples with \geq 1 *SMN1* copies (N = 44), *SMN2* dosage status was determined by the AmplideX® PCR/CE *SMN1/2* Plus Kit as previously described

(23). In addition, this method was utilized to assess both *SMN1* and *SMN2* copy
number for all cell line and presumed normal whole blood samples during assay
development and optimization.

181

PCR and Nanopore Sequencing (PCR/Nanopore)

183 The prototype assay workflow includes PCR master mix setup, gene-specific amplification, sample specific barcoding, paramagnetic bead size selection and 184 185 concentration, library adapter ligation, Nanopore sequencing, and assay-specific 186 analysis pipelines (Figure 1). Roughly 40ng gDNA was amplified by multiplex PCR 187 targeting 2.7kb regions of SMN1 or SMN2 exons 7-8 and copy number neutral 188 endogenous control amplicons from CFTR in one mix or a larger 11.2kb amplicon 189 encompassing exons 3-8 in a separate mix. Reactions were cleaned up using 0.6X 190 AMPure XP bead ratio (Beckman Coulter, Indianapolis, IN). Samples were tagged 191 with unique barcodes during a second PCR reaction, normalized by mass after Qubit 192 quantitation (Invitrogen, Carlsbad CA), pooled into a single reaction, and 193 concentrated using 0.6X AMPure XP bead ratio.

194

Sequencing libraries were prepared using the Nanopore Ligation Sequencing Kit (LSK-110 or LSK-114; ONT). Sequencing was conducted using MinKNOW software (22.10.10) on MinION flow cells (R9.4.1 or R10.4.1) with a Mk1B sequencer connected to a computer. Sequencing proceeded for at least 5 hours to obtain a minimum of 150 fully-spanning reads per copy per region. Super-accurate base calling was performed using Guppy (6.3.9) after sequencing and fully spanning reads were aligned to GRCh38 using minimap2 (2.15+dfsg-1).

203 To determine copy number, we trained a gradient boosting tree model to predict 204 copy number using the ratio of Cs and Ts at the paralog specific variant c.840C>T in 205 exon 7 (NM_000344.3c.840C>T; Single Nucleotide Polymorphism database, 206 https://www.ncbi.nlm.nih.gov/snp, accession number rs1164325688, build 155, last accessed August 15th, 2023) (**Supplemental Figure 1**). The model incorporates 207 208 read depth of fully spanning 2.7kb fragments aligned to SMN1 (c.840C) or SMN2 209 (c.840T) and the geometric mean of endogenous control amplicons (CFTR) to infer 210 fold change based on normalized read depth in 2-copy calibrator samples 211 (Supplemental Figure 2). The machine learning algorithm was trained on a subset 212 of cell lines (N=79) and an independent set of residual whole blood samples 213 (N=352). Hyperparameters for the decision tree model were selected using an 80:20 214 train:test split in a stratified randomly selected five-fold cross validation scheme.

215

216 Additionally, SMN1 and SMN2 copy number was informed with the longer 11.2kb 217 amplicon flagged as edge cases where the machine learning algorithm predicted a 218 copy number of 2.25 to 2.75. First, unique haplotype groups were identified and 219 differentiated by sequence variability (e.g. SNVs) corresponding to unique copies 220 aligning to the same region of the genome (**Supplemental Figure 3**). This allows for 221 the identification of all unique copies for a gene target, and thus can be used to 222 inform copy number calls and provide proper input to variant calling software that 223 often assumes no more than two copies of the gene are present. Group sizes were 224 normalized according to read depth and copy number was inferred for each group. 225 The number of normalized haplotype groups were reported as the predicted copy 226 number for samples that were flagged as edge cases when more than one group 227 was identified.

Predicted copy number from the PCR/Nanopore assay was compared to data collected by orthogonal methods (ddPCR and/or PCR/CE). Small nucleotide variants and insertion/deletions were identified using Clair3 (24).

- 231
- 232 **Results**

233 Assay Development and Optimization

234 We developed a complementary, two-in-one MinION-based assay utilizing amplicons 235 ranging more than 10-fold in length, including reference loci, to identify SMN1 and 236 SMN2 variants. Assay designs and analysis methods were optimized for copy 237 number changes and phased SNVs and indels (Figure 1). Primers were developed 238 to amplify ~800-3000 base fragments ("short" amplicons) encompassing both SMN1 239 and SMN2 exon 7-8 and endogenous controls (Supplemental Figure 2). The assay 240 assesses SMN1 or SMN2 copy number by aligning reads spanning exons 7 and 8 to 241 either SMN1 or SMN2, then determining the raw read depth and ratio of reads 242 associated with c.840C (SMN1) or c.840T (SMN2). A machine learning method 243 infers copy number by comparing the C:T ratio in exon 7 and corresponding read 244 depths to endogenous control amplicons in calibrator samples.

245

We also designed primers to amplify an 11.2kb fragment ("long" amplicon) encompassing exons 3-8 to enhance phasing SNVs in *SMN1* or *SMN2* (**Supplemental Figure 3**). This long amplicon typically captures several paralogspecific variants and facilitates sequence deconvolution of reads into haplotype groups to infer copy number. In some samples, however, there are no copy distinguishing sequence variants within one or both paralogs to independently resolve copy number.

253

254 The assay was developed and evaluated in three phases (Figure 2). In the 255 prototyping phase, gene-specific primers, protocols, and reagents were designed 256 and tested on a diverse set of cell line (N=79) and presumed normal whole blood 257 (N=352) samples. This set included independently analyzed SMN1 and SMN2 258 genotypes ranging from 0 to \geq 4 copies along with SNVs and Indels described below. 259 Sequencing data were collected with short and long amplicons. Algorithms were 260 trained using amplicon sequence and read depth within SMN1 and SMN2 compared 261 to known genotypes for each sample. We also identified endogenous control 262 amplicons and calibrator samples to convert SMN1 and SMN2 read-depth ratios into 263 copy numbers.

264

In the assay optimization phase, performance was first evaluated with the short, 265 2.7kb amplicon design utilizing a sample cohort of 18 additional cell lines (N=97 267 total) and an independent set of whole-blood samples (N=227) across 0 to \geq 3 *SMN1* 268 and *SMN2* copies (**Figure 33**). Assay copy number predictions were compared to 269 PCR/CE data and segregated by sample type.

270

Copy number agreement was 97.9% (95/97) between PCR/Nanopore and comparator method for both *SMN1* and *SMN2* in the cell-line set. One sample (NA20232) was discordant for both *SMN1* and *SMN2*. This cell line was expected to be 3 copy *SMN1* and 2 copy *SMN2* (3/2) by PCR/CE yet reported as 2/1 by the PCR/Nanopore assay. Two other samples had either *SMN1* or *SMN2* discordant copy number data where a 3 copy was expected, yet a 2 copy was predicted by the

algorithm. In each case, haplotype deconvolution with the long amplicon supported
the expected copy number.

279

280 In the whole blood sample cohort, 218/227 (96.0%) SMN1 and 224/227 (98.7%) 281 SMN2 copy number calls agreed between PCR/Nanopore and comparator method. 282 Of the 9 discordant samples for SMN1, 7 discordant samples had more than one 283 haplotype. We used the long amplicon design to investigate these discordances, 284 consistent with methods described. Six of the seven samples agreed with 285 comparator data when both amplicon designs were utilized. Four of 9 discordant 286 samples were flagged as edge cases at or near the call threshold with the short 287 amplicon and 3 were resolved by haplotype deconvolution with the long amplicon 288 design.

289

290 Consequently, we applied the flagging QC across the entire dataset to determine the 291 effect on accuracy (Figure 33). One cell line and 12 whole blood samples were 292 flagged as edge cases at or near the call threshold with the 2.7kb amplicon for 293 SMN1. Of these, 4 were discordant using the short amplicon alone, but 3 were 294 corrected by calls using the long amplicon. Similarly, of the 3 SMN2 calls flagged 295 only 1 was discordant and long amplicon design supported the expected copy 296 number. In no instance was a sample flagged where the long amplicon call 297 disagreed with comparator data when at least 2 haplotype groups were identified. As 298 a result, both amplicon designs were used for all subsequent analyses where call 299 threshold flagging prioritized the long amplicon copy number call.

301 In addition to copy number evaluation, the assay was designed to identify and phase 302 SNVs and indels without reflexing to other assays. For example, the SMN2, NM_017411.3: c.859G>C variant (dbSNP, rs121909192, build 155, last accessed 303 August 15th 2023) is associated with a less severe SMA phenotype (25, 26, 27, 28). 304 305 Two variants linked with the SMN1 duplication haplotype have been shown to flag 306 silent carriers and increase carrier detection rates when 2 SMN1 copies occur on the NM 000344.3:c.*3+80T>G (alias 307 chromosome. These variants are same g.27134T>G; dbSNP, rs143838139, build 155, last accessed August 15th 2023) and 308 NM 000344.3: c.*211 *212del (alias g.27706 27707delAT; dbSNP, rs200800214, 309 build 155, last accessed August 15th 2023). 310

311

312 PCR/Nanopore genotyping of these variants agreed with the PCR/CE comparator 313 method in 324/324 samples for c.*3+80T>G and c.859G>C, and in 322/324 (99.4%) 314 for c.*211_212del (Figure 4). Investigation of the two discordant samples suggested 315 erroneous comparator data. In HG00691, a rare non-pathogenic deletion in SMN2 316 (rs576032516) shifted a CE peak into the mutant CE bin, resulting in a false positive. 317 In the second sample, the automated peak caller in the CE assay incorrectly called noise along the baseline within the c.*211_212del bin, resulting in another false 318 319 positive call.

320

321 Independent Evaluation of Residual Clinical Samples

Next, we evaluated assay performance across a diverse, independent cohort of samples from 70 individuals (57% females, average age 2.17 years, range 1 day – 16 years) with known *SMN1* and *SMN2* copy number status originally tested at Al

325	Jalila Children's Specialty Hospital, Dubai, UAE. Those individuals represented 14
326	countries, primarily from the Middle East and North Africa (Supplemental Table 2).
327	
328	Of all individuals, 30 (42.9%) had homozygous deletions in the SMN1 gene, while
329	the remaining 40 (57.1%) had 1 to 4 copies of this gene. Sixty-seven of the 70
330	samples were also evaluated for SMN2 copy number. Most individuals (58%) had 2
331	SMN2 copies, 10% had 0 copies and 42% had 1, 3, or \geq 4 copies of this gene
332	(Supplemental Table 3).
333	

The PCR/Nanopore assay correctly identified 70/70 and 65/67 of *SMN1* and *SMN2*copy number states for a concordance rate of 100% (95% CI, 94.80% - 100.00 %)
and 97.0% (95% CI, 89.75% - 99.18%), respectively (**Table 1**).

337

338 Cost Effectiveness and Hand-On Time

The accessibility and broad use of an *SMN1/2* screening and genotyping assay depends on numerous criteria, including performance, operational factors and cost. Assay workflow, analysis and economic considerations are especially important for laboratories in lower resource environments. We assessed these elements by performing a time-motion analysis, quantifying the scalability of the assay across different sample batch volumes, and calculating estimated costs per sample.

345

Time-motion analysis was estimated across 6 operators based on experience for both a 24- and 96-sample batch (**Supplemental Table 4**). The workflow from sample to answer requires less than 48 hours for a 24-sample batch on a Mk1B connected to a computer with a recommended GPU. Gene-specific and barcoding PCR can be

completed in a single work shift. Subsequently, samples can be pooled, the library
 prepared, and sequencing initiated with sequencing and analysis completed
 overnight for review the next day. A 96-sample batch required additional sequencing
 and data processing time but was still completed within 72 hours.

354

355 The assay supports 12 to 96 samples per batch (Supplemental Table 5). Batch 356 size is currently only limited by the recommended barcodes available from ONT 357 (N=96) since flow cells can routinely process >10M reads. A single Mk1B running 12 358 samples once per week could screen 624 samples per year. By comparison, 480 359 samples could be processed per batch on one GridION with 5 independently 360 accessible flow cells, real-time base calling, demultiplexing, and alignment. Utilizing 361 3 staggered run batches per week a lab could process 75,000 samples per year. 362 This throughput can scale linearly by adding additional GridION instruments. In 363 addition, the assay supports automated reaction setup, bead isolation, quantitation, 364 and data analysis to further improve workflow efficiency.

365

366 We estimated less than \$20 USD per sample for materials costs excluding PCR 367 (Supplemental Table 6). Since the assay is still in development, PCR enrichment 368 costs cannot be accurately determined. For example, the assay design must be 369 finalized and verified, reagents and kits manufactured, and guality control and 370 release testing established. However, PCR is well documented to be highly cost-371 effective at scale, and we expect that the total per-sample costs will be comparable 372 to other SMN1/2 diagnostic kits that provide far less genotyping information and 373 insight. These costs also do not include instrument-related expenses. Importantly, 374 ONT instruments (e.g. Mk1B and GridION) have low capital requirements and

benchtop footprints, which creates flexibility for laboratories in how they implement
the technology. For either instrument, a computer is required for data analysis. For
Mk1B instruments, the computer must be equipped with a high-performance GPU to
utilize live basecalling, demultiplexing, and alignment during sequencing.

379

380 **Discussion**

We developed a novel dual-mode PCR/Nanopore sequencing assay for comprehensive, scalable and cost-effective *SMN1/2* genotyping. The assay design utilizes a PCR target enrichment approach to generate 2.7kb "short" and 11.2kb "long" amplicons spanning regions of the *SMN1* and *SMN2* genes, as well as a machine learning-based analytical pipeline haplotype phasing and read depth data to decipher sequence and copy number variants specific to both highly homologous genes.

388

389 Data from both amplicons were combined to achieve the highest accuracy for the 390 prototype assay (>97%). Other long-read sequencing designs utilize only phased 391 haplotype analysis either by hybrid capture (20) or multiple ultra-long (>26kb) 392 amplicons on the PacBio SMRT platform (19). Robustness may be adversely 393 affected by identical haplotypes without read depth normalized to endogenous and 394 exogenous control amplicons. Indeed, we observed identical haplotype groups in our 395 sample set when only the long amplicon was used for copy number evaluation. In 396 contrast, the PCR/Nanopore assay utilizes a combination of read-depth 397 normalization (short amplicon) and haplotype phasing (long amplicon) to resolve 398 SMN1 and SMN2 copy number and phase pathogenic SNV/introns. In addition, the 399 assay scales from tens to tens of thousands of samples per year with reduced

400 capital and per-sample costs compared to other sequencing-based assays.
401 Reducing costs is critical for many existing screening labs or those looking to adopt
402 such screening assays, as reimbursement costs are not always able to cover test
403 costs with NGS workflows. Lastly, the assay includes analysis and reporting software
404 to reduce interpretation expertise and overhead, though the full suite of push-button
405 automated analysis software is still in development.

406

407 We acknowledge a few limitations of the current study. The optimized prototype was 408 designed to phase variants across SMN1 or SMN2 exons 3-8. Although we 409 demonstrated variant phasing with non-pathogenic silent carrier and disease 410 modifier SNVs, full exon coverage of SMN1 and SMN2 is preferred to assess all 411 potential SNV/indel variants. In ongoing work, we have extended the assay design to 412 cover exons 1, 2a, and 2b, though performance has not yet been evaluated. Further, 413 amplification efficiency must be optimized to reduce read depth variability between 414 samples by optimizing primers and cycling conditions. These modifications are 415 expected to improve the resolution and differentiation of 3- and 4-copy genotypes, 416 especially important for treatment decisions that may rely on accurate high copy 417 number SMN2 calls when SMN1 is not detected. We have also begun evaluating 418 additional endogenous control amplicons to improve accuracy. Finally, we 419 recognized that amplicon-based methods can be affected by sample-specific SNVs 420 in primer-binding regions. This risk was reduced by utilizing two different primer sets 421 across different amplicon sizes to resolve copy number.

422

In summary, we present results from the development, optimization, and external
 evaluation of a novel PCR/Nanopore assay using over 750 samples, including cell

425 lines, residual presumed normal blood donors, and patient specimens with known 426 SMN1 and SMN2 genotypes. The results reveal accurate detection of multiple 427 categories of clinically informative variants, including SNVs, indels and CNVs. SNV 428 phasing was demonstrated through known silent carrier (2+0) and disease-modifier 429 variants. Importantly, the assay is cost-effective and scalable, showing potential for 430 broad implementation in diagnostic and screening programs. Last, we note a key 431 benefit of the assay chemistry, platform and workflow is its flexibility to include 432 additional, variants in CFTR, FMR1, and HBA1/2 and other genes associated with 433 commonly screened genetic disorders. This extensibility may further expand the 434 utility of the approach and application and represents an important future direction 435 for technology development.

436

437 **Funding**

This work received funding support from Asuragen and Oxford NanoporeTechnologies in the form of reagents and consumables.

440

441 **Conflict of Interest**

BH, BK, and GL are employees of Bio-Techne with stock and stock options in thiscompany.

444

445 **Acknowledgements**

446 We would like to thank all members of Al Jalila Children's Genomics Center,

447 Asuragen, and Oxford Nanopore Technologies, specifically Frédérique Lerêteux,

Rita Aoun, and Hannah Lucio, for their valuable input on this work.

450 **References**

451	1. D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy.	

- 452 Orphanet J Rare Dis 2011;6:71. <u>https://pubmed.ncbi.nlm.nih.gov/7813012/</u>
- 453
- 454 2. Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al.
- ⁴⁵⁵ Identification and characterization of a spinal muscular atrophy-determining gene.
- 456 Cell 1995;80:155-65. <u>https://www.ncbi.nlm.nih.gov/pubmed/7813012/</u>
- 457
- 458 3. Roy N, Mahadevan MS, McLean M, Shutter G, Zahra Yaraghi, Reza Zanjirani
- 459 Farahani, et al. The gene for neuronal apoptosis inhibitory protein is partially
- deleted in individuals with spinal muscular atrophy. Cell 1995;80:167–78.
- 461
- 462 4. Thompson TG, DiDonato CJ, Simard LR, Ingraham SE, Burghes AH, Crawford
- 463 TO, et al. A novel cDNA detects homozygous microdeletions in greater than 50%
- of type I spinal muscular atrophy patients. Nat Genet 1995;9:56-62.
- 465 https://pubmed.ncbi.nlm.nih.gov/7704025/
- 466
- 5. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy [Internet]. Adam
- 468 MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al., editors.
- 469 PubMed. Seattle (WA): University of Washington, Seattle; 1993.
- 470 https://pubmed.ncbi.nlm.nih.gov/20301526/

- 472 6. Wadman RI, Jansen MD, Stam M, Wijngaarde CA, Curial CAD, Medic J, et al.
- Intragenic and structural variation in the SMN locus and clinical variability in

474	spinal muscular atrophy [Internet]. Brain Commun 2020;2:fcaa075
475	https://pubmed.ncbi.nlm.nih.gov/32954327/
476	
477	7. Chen X, Sanchis-Juan A, French CE, Connell AJ, Delon I, Kingsbury Z, et al.
478	Spinal muscular atrophy diagnosis and carrier screening from genome
479	sequencing data. Genetics in Medicine 2020;22:945-53.
480	https://www.nature.com/articles/s41436-020-0754-0#ref-CR6
481	
482	8. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN
483	gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl
484	Acad Sci 1999;96:6307–11
485	https://www.pnas.org/content/96/11/6307.short
486	
487	9. Coovert DD, Le TT, McAndrew PE, Strasswimmer J, Crawford TO, Mendell
488	JR, et al. The Survival Motor Neuron Protein in Spinal Muscular Atrophy. Hum
489	Mol Genet 1997;6:1205–14.
490	
491	10. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, et al.
492	Molecular analysis of spinal muscular atrophy and modification of the phenotype
493	by SMN2. Genet Med 2002;4:20–6. https://www.nature.com/articles/gim20024
494	
495	11. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, et al.
496	Correlation between severity and SMN protein level in spinal muscular atrophy.
497	Nature genetics. 1997;16:265–9.
498	https://www.ncbi.nlm.nih.gov/pubmed/9207792

499	
500	12. The American College of Obstetricians and Gynecologists. Committee
501	Opinion No. 691. Obstetrics & Gynecology. 2017;129:e41–55.
502	
503	
504	13. Prior TW, Nagan N, Sugarman EA, Batish SD, Braastad C. Technical
505	standards and guidelines for spinal muscular atrophy testing. Genet Med
506	2011;13:686–94.
507	
508	14. Campbell L, Potter A, Ignatius J, Dubowitz V, Davies K. Genomic Variation
509	and Gene Conversion in Spinal Muscular Atrophy: Implications for Disease
510	Process and Clinical Phenotype. The American Journal of Human Genetics
511	1997;61:40–50.
512	
513	15. Luo M, Liu L, Peter I, Zhu J, Scott SA, Zhao G, et al. An Ashkenazi Jewish
514	SMN1 haplotype specific to duplication alleles improves pan-ethnic carrier
515	screening for spinal muscular atrophy. Genet Med 2013;16:149–56.
516	
517	16. Abou Tayoun AN, Burchard PR, Malik I, Scherer A, Tsongalis GJ.
518	Democratizing Molecular Diagnostics for the Developing World. American Journal
519	of Clinical Pathology. 2014;141:17-24.
520	https://academic.oup.com/ajcp/article/141/1/17/1766064
521	

522	17. Abou Tayoun AN. Unequal global implementation of genomic newborn
523	screening. Nature Reviews Genetics 2023;24:801-2.
524	https://pubmed.ncbi.nlm.nih.gov/37723349/
525	
526	18. Sa'adah N, Harahap NIF, Nurputra DK, Rochmah MA, Morikawa S,
527	Nishimura N, et al. A Rapid, Accurate and Simple Screening Method for Spinal
528	Muscular Atrophy: High-Resolution Melting Analysis Using Dried Blood Spots on
529	Filter Paper. Clinical Laboratory 2015;61:575–80.
530	https://pubmed.ncbi.nlm.nih.gov/26118191/
531	
532	19. 1.Li S, Han X, Xu Y, Chang C, Gao L, Li J, et al. Comprehensive analysis of
533	spinal muscular atrophy (CASMA): SMN1 copy number, intragenic mutation and
534	2 + 0 carrier analysis by third-generation sequencing. J Mol Diagnostics 2022;
535	24:1009–20.
536	
537	20. Chen X, Harting J, Farrow EG, Thiffault I, Kasperaviciute D, Hoischen A, et
538	al. Comprehensive SMN1 and SMN2 profiling for spinal muscular atrophy
539	analysis using long-read PacBio HiFi sequencing. Am J of Hum Genetics
540	2023;110:240–50.
541	
542	21. Budimirovic DB, Schlageter A, Filipovic-Sadic S, Protic DD, Bram E, Mahone
543	EM, et al. A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid
544	and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments.
545	Brain Sci 2020;10:694.
546	https://www.mdpi.com/2076-3425/10/10/694/htm

547	

548	22. Naofal ME, Ramaswamy S, Alsarhan A, Nugud A, Sarfraz F, Janbaz H, et al.
549	The genomic landscape of rare disorders in the Middle East. Genome Med
550	2023;15:5.
551	
552	23. Milligan JN, Larson JL, Filipovic-Sadic S, Laosinchai-Wolf W, Huang Y-W, Ko
553	T-M, et al. Multisite Evaluation and Validation of a Sensitive Diagnostic and
554	Screening System for Spinal Muscular Atrophy that Reports SMN1 and SMN2
555	Copy Number, along with Disease Modifier and Gene Duplication Variants. J Mol
556	Diagn 2021;23:753–64.
557	https://pubmed.ncbi.nlm.nih.gov/33798739/
558	
559	24. Zheng Z, Li S, Su J, Leung AW, Lam T, Luo R. Symphonizing pileup and full-
560	alignment for deep learning-based long-read variant calling. Nat Comput Sci
561	2022;2:797-803.
562	
563	25. Vezain M, Saugier-Veber P, Goina E, Touraine R, Manel V, Toutain A, et al.
564	A rare SMN2 variant in a previously unrecognized composite splicing regulatory
565	element induces exon 7 inclusion and reduces the clinical severity of spinal
566	muscular atrophy. Human Mutation 2010;31:E1110–25.
567	
568	26. Ruhno C, McGovern VL, Avenarius MR, Snyder PJ, Prior TW, Nery FC, et al.
569	Complete sequencing of the SMN2 gene in SMA patients detects SMN gene
570	deletion junctions and variants in SMN2 that modify the SMA phenotype. Human

- 571 genetics 2019;138:241–56.
- 572 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503527/
- 573
- 574 27. Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al.
- 575 Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N
- 576 Engl J Med 2017;377:1723–32.
- 577 https://www.ncbi.nlm.nih.gov/pubmed/29091570
- 578
- 28. Pechmann A, Langer T, Schorling D, Stein S, Vogt S, Schara U, et al.
- 580 Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within
- the Expanded Access Program in Germany. J Neuromuscul Dis 2018;5:135–43.
- 582 https://www.ncbi.nlm.nih.gov/pubmed/29689734
- 583
- 584
- 585
- 586
- 587
- 588
- 589
- 590
- 591
- _ _
- 592
- **Table 1.** PCR/Nanopore assay performance based on concordance data using clinical samples with known SMN1/2 copy number status.
- 595

COPY NUMBER NUMBER OF CLINICAL BLOOD SAMPLES (BOTH DESIGNS)

	STATE	SMN1 (N=70)	<i>SMN2</i> (N = 67)
	0	30/30	7/7
	1	8/8	7/7
	2	22/22	37/39
	≥ 3	10/10	14/14
596			
597			
598			

599 Figure Legends

600 Figure 1. The prototype PCR/Nanopore Assay design and workflow involves two separate PCR reactions that amplify either 2.7kb or 11.2kb amplicon products. 601 602 Amplicons are barcode tagged for each sample in a second PCR reaction, then pooled by mass into a single sequencing library. The library is prepared by 603 appending nanopore-specific adaptors and loaded into a MinION flowcell for 604 605 sequencing on a Mk1B connected to a computer running MinKNOW software 606 (Oxford Nanopore Technologies). Data are analyzed with off-the-shelf and assayspecific software. 607

Figure 2. Study design for assay development consisted of three phases.

Figure 3. Performance of the assay to identify copy number across cell lines or presumed normal whole blood samples within the optimization data set for SMN1 (orange) or SMN2 (blue) utilizing the 2.7kb fragment or both designs where call threshold flagging would prioritize the copy number call from the 11.2kb amplicon. Genotype agreement was >97% for both SMN1 and SMN2 using both designs, and 100% for the limited number of 0 and 1 copy SMN1 samples in this data set.

Figure 4. Confusion matrix comparing the expected and predicted SNVs associated with silent carrier or disease modifier risk. The algorithm accurately identified each variant type except for two. †Inspection of the underlying trace data for these two samples in the comparator assay revealed a profile consistent with false-positive calls and a defined root cause in each case. This correction would result in 100% agreement across each variant for the PCR/Nanopore assay.



Prototyping Phase

79 Cell Lines 352 Whole Blood

Combine multiplex primer design, reagents, algorithms, and protocol into a proof-ofconcept assay with known samples across a collection of diverse *SMN1* and *SMN2* copy number samples.



Optimization Phase

97 Cell Lines (79 + 18 new) 227 new Whole Blood

Optimize performance on a partially independent set of samples that exemplifies *SMN1* and *SMN2* copy numbers associated with screening and diagnostics, across operators, instruments, and input quantities.

Evaluation Phase

70 Clinical Samples



Evaluate assay performance across an independent clinical cohort of patients from 15 primarily Middle East and North Africa countries.





Whole Blood

201

87

0

1 2 Predicted

114

2

≥3

Genotype Agreement

	SMN1	SMN2	<i>SMN1</i> 0 or 1 cp
Cell	95/97	95/97	12/12
Line	(97.9%)	(97.9%)	(100%)
Whole	218/227	224/227	2/2
Blood	(96.0%)	(98.7%)	(100%)

	SMN1	SMN2	S <i>MN1</i> 0 or 1 cp
Cell	95/97	96/97	12/12
Line	(97.9%)	(99.0%)	(100%)
Whole	221/227	224/227	2/2
Blood	(97.3%)	(98.7%)	(100%)







c.*3+80T>G



c.*211_212del

c.859G>C







Predicted